KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Non Operating Income (2019 - 2025)

Historic Non Operating Income for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to -$32.5 million.

  • Royalty Pharma's Non Operating Income fell 1953.39% to -$32.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$235.3 million, marking a year-over-year decrease of 71332.59%. This contributed to the annual value of -$235.3 million for FY2025, which is 71332.33% down from last year.
  • Latest data reveals that Royalty Pharma reported Non Operating Income of -$32.5 million as of Q4 2025, which was down 1953.39% from $17.1 million recorded in Q3 2025.
  • Royalty Pharma's 5-year Non Operating Income high stood at $113.8 million for Q2 2022, and its period low was -$127.4 million during Q4 2022.
  • Moreover, its 5-year median value for Non Operating Income was -$28.3 million (2023), whereas its average is -$12.8 million.
  • As far as peak fluctuations go, Royalty Pharma's Non Operating Income plummeted by 28972.86% in 2021, and later skyrocketed by 34275.16% in 2024.
  • Over the past 5 years, Royalty Pharma's Non Operating Income (Quarter) stood at -$99.7 million in 2021, then decreased by 27.7% to -$127.4 million in 2022, then surged by 182.19% to $104.7 million in 2023, then crashed by 125.95% to -$27.2 million in 2024, then dropped by 19.53% to -$32.5 million in 2025.
  • Its last three reported values are -$32.5 million in Q4 2025, $17.1 million for Q3 2025, and -$119.2 million during Q2 2025.